Perspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III Buys 30,031 Shares

Perspective Therapeutics, Inc. (NYSE:CATXGet Free Report) Director Robert F. Williamson III bought 30,031 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The stock was purchased at an average cost of $1.33 per share, with a total value of $39,941.23. Following the purchase, the director now directly owns 368,792 shares in the company, valued at approximately $490,493.36. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Perspective Therapeutics Stock Performance

NYSE CATX opened at $1.32 on Friday. The company has a current ratio of 12.98, a quick ratio of 12.98 and a debt-to-equity ratio of 0.01. Perspective Therapeutics, Inc. has a one year low of $0.21 and a one year high of $1.91.

Perspective Therapeutics (NYSE:CATXGet Free Report) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. Perspective Therapeutics had a negative return on equity of 46.38% and a negative net margin of 302.70%. The company had revenue of $0.33 million for the quarter. Analysts forecast that Perspective Therapeutics, Inc. will post -0.11 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. B. Riley boosted their price objective on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a research report on Tuesday, April 9th. Lifesci Capital reissued an “outperform” rating on shares of Perspective Therapeutics in a research note on Monday, May 6th. Cantor Fitzgerald started coverage on Perspective Therapeutics in a research report on Thursday, May 9th. They issued an “overweight” rating for the company. Royal Bank of Canada initiated coverage on Perspective Therapeutics in a research report on Tuesday, May 14th. They set an “outperform” rating and a $3.00 target price on the stock. Finally, Oppenheimer restated an “outperform” rating and issued a $1.50 price target (up previously from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $1.90.

Get Our Latest Stock Analysis on Perspective Therapeutics

Institutional Trading of Perspective Therapeutics

Several large investors have recently bought and sold shares of the company. Janus Henderson Group PLC acquired a new position in Perspective Therapeutics in the first quarter worth about $15,511,000. Affinity Asset Advisors LLC acquired a new position in shares of Perspective Therapeutics in the 1st quarter worth approximately $6,069,000. Vanguard Group Inc. increased its holdings in shares of Perspective Therapeutics by 34.6% in the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after acquiring an additional 4,566,356 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of Perspective Therapeutics during the 3rd quarter valued at approximately $314,000. Finally, Bank of New York Mellon Corp bought a new position in Perspective Therapeutics during the third quarter worth $42,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

(Get Free Report)

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

Recommended Stories

Insider Buying and Selling by Quarter for Perspective Therapeutics (NYSE:CATX)

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.